Lenalidomide Plus R‐gdp (R2‐gdp) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Preliminary Results of the R2‐gdp‐gotel Trial

Cruz-Merino, Luis de la; García-Sancho, Alejandro Martín; Fernández, Esteban Nogales; González, Fernando Carnicero; Herranz, Eduardo Ríos; Vicente, F. de la Cruz; Garcia, Gabriel; García, C. Nicolás; Benaclocha, N. Martínez; Padró, Josep Gumà; Codina, José; Silvestre, Antonio Salar; Rodríguez-Abreu, Delvys; Blanco, C. Quero; Gómez, Jorge Labrador; Risueño, M. Guirado; Pulla, M. Provencio; Domı́nguez, A.

doi:10.1002/hon.67_2630

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In R/R DLBCL, rituximab combined with lenalidomide (R2) has been used alone [22] or combined with GDP (gemcitabine, cisplatin, and dexamethasone) [23], obtaining promising responses. In the same line, R2-GDP was used as an alternative schedule in R/R DLBCL patients from the study "Phase II clinical trial to evaluate the combination of lenalidomide with R-GDP in patients diagnosed with R/R DLBCL not candidates for high-dose chemotherapy and hematopoietic progenitor cell transplantation" (EudraCT Number: 2014-001620-29), performed by the Spanish Lymphoma Oncology Group (GOTEL), reporting promising objective response rates (ORR) [24,25] and the depletion of immune suppressor cells in patients with an overall survival (OS) longer than 24 months [26].…”

Section: Introductionmentioning

confidence: 99%

Lower Survival and Increased Circulating Suppressor Cells in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Deficit of Vitamin D Levels Using R-GDP Plus Lenalidomide (R2-GDP): Results from the R2-GDP-GOTEL Trial

Jiménez‐Cortegana

Sánchez-Martínez

Palazón‐Carrión

et al. 2021

Cancers

View full text Add to dashboard Cite

The search of prognostic factors is a priority in diffuse large B-cell lymphoma (DLBCL) due to its aggressiveness. We have recently found that the level of circulating MDSCs is a good marker of survival in a translational study based on a trial (EudraCT Number: 2014-001620-29), using lenalidomide combined with R-GDP (rituximab plus gemcitabine, cisplatin, and dexamethasone). Since Vitamin D is a known immunomodulator, we have studied blood levels of these cell populations comparing patients with deficit of vitamin D levels (<15 ng/mL with those with normal levels >15 ng/mL. Mann–Whitney U test was used to compare cells distributions between groups, Wilcoxon test to compare cells distribution at different times and Spearman test to measure the association between cell populations. Patients with vitamin D deficit maintained the increased level of immune suppressor cells, whereas we observed a depletion of all immune suppressor cells in patients with normal vitamin D levels. In conclusion, we have confirmed the importance of vitamin D in the response to treatment in R/R DLBCL, suggesting that vitamin D deficit may be involved in the immune deficit of these patients, and thus, vitamin D supplementation in these patients may help to obtain a better response, warranting further investigation.

show abstract